TTCI Congratulates Assoc. Prof. Dr. Jakkarawadee Julamanee on Receiving Prestigious National Research and Innovation Awards
October 16, 2026
SONGKHLA, THAILAND – The Thailand Hub of Talents in Cancer Immunotherapy (TTCI) proudly congratulates Assoc. Prof. Dr. Jakrawadee Julamanee, M.D., Ph.D., from the Faculty of Medicine, Prince of Songkla University (PSU) and a valued member of the TTCI network, on receiving recognition through two prestigious national awards in 2026.
These distinguished honors celebrate her contributions to medical research, service innovation, and the advancement of CAR-T cell therapy, reflecting her dedication to improving access to innovative cancer treatments in Thailand.
Recognizing Excellence in Medical Research
Assoc. Prof. Dr. Jakrawadee received the prestigious “Jongjet Nivatvongs” Outstanding Medical Researcher Award 2026 (รางวัลจงเจตน์นิวัฒน์ แพทย์นักวิจัยดีเด่น ประจำปี 2569), presented by the Medical Research Support Center, The Medical Council of Thailand.
This national recognition honors her achievements in medical research and her contributions to advancing innovative therapeutic approaches, particularly in the field of cellular immunotherapy.
National Recognition for PSU CAR-T Cell Service Innovation
The คณะแพทยศาสตร์ มหาวิทยาลัยสงขลานครินทร์ was also honored with the 2026 Public Service Award (Lert-Rat Award): Good Level in Service Innovation (รางวัลเลิศรัฐ ประจำปี 2569: รางวัลบริการภาครัฐ ระดับดี ประเภทนวัตกรรมการบริการ).
The award recognizes the innovative healthcare project entitled:
“มะเร็งร้ายหายได้ด้วย PSU CAR-T Cell”
This achievement highlights the university's commitment to developing innovative cancer treatment services and strengthening access to advanced cellular therapies through academic research and clinical innovation.
The recognition also reflects the collaborative efforts of the PSU medical and research teams in translating scientific advances into practical healthcare applications.
Pioneering Clinical Research in PSU CAR-T Cell Therapy
As a leading principal investigator, Assoc. Prof. Dr. Jakrawadee Julamanee has played a central role in advancing CAR-T cell therapy research and clinical development at Prince of Songkla University.
One of her notable research initiatives is the clinical study entitled:
“Phase 1/2 Clinical Study to Assess the Safety and Efficacy of PSU CD19CAR-T Cell in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)”
Supported by PMU-ข, this study focuses on evaluating the safety and efficacy of locally developed CD19-directed Chimeric Antigen Receptor T-cell (CAR-T) therapy for patients with relapsed or refractory diffuse large B-cell lymphoma.
The research represents an important step toward strengthening Thailand's capacity to develop advanced cellular therapies and expanding potential treatment options for patients with difficult-to-treat hematologic malignancies.
Advancing Cancer Immunotherapy and Healthcare Innovation in Thailand
These national recognitions underscore the importance of integrating scientific research, clinical innovation, and healthcare service development to address the needs of cancer patients.
Through her leadership and dedication, Assoc. Prof. Dr. Jakrawadee continues to contribute to the advancement of academic CAR-T cell therapy, strengthening domestic research capabilities and supporting the development of innovative cancer treatment approaches in Thailand.
Her achievements also demonstrate the growing potential of Thai academic institutions to develop advanced biotherapies and translate research discoveries into meaningful clinical applications.
Celebrating Outstanding Research Leadership and Medical Innovation
The Thailand Hub of Talents in Cancer Immunotherapy (TTCI) extends its warmest congratulations to Assoc. Prof. Dr. Jakrawadee Julamanee and the คณะแพทยศาสตร์ มหาวิทยาลัยสงขลานครินทร์ on these remarkable national achievements.
These prestigious recognitions reflect her scientific excellence, visionary leadership, and dedication to advancing cancer immunotherapy research and healthcare innovation.
TTCI proudly celebrates these achievements and remains committed to fostering collaborative research, supporting scientific innovation, and advancing accessible cancer immunotherapy for patients across Thailand.
Official Website: www.ttci-th.org
These distinguished honors celebrate her contributions to medical research, service innovation, and the advancement of CAR-T cell therapy, reflecting her dedication to improving access to innovative cancer treatments in Thailand.
Recognizing Excellence in Medical Research
Assoc. Prof. Dr. Jakrawadee received the prestigious “Jongjet Nivatvongs” Outstanding Medical Researcher Award 2026 (รางวัลจงเจตน์นิวัฒน์ แพทย์นักวิจัยดีเด่น ประจำปี 2569), presented by the Medical Research Support Center, The Medical Council of Thailand.
This national recognition honors her achievements in medical research and her contributions to advancing innovative therapeutic approaches, particularly in the field of cellular immunotherapy.
National Recognition for PSU CAR-T Cell Service Innovation
The คณะแพทยศาสตร์ มหาวิทยาลัยสงขลานครินทร์ was also honored with the 2026 Public Service Award (Lert-Rat Award): Good Level in Service Innovation (รางวัลเลิศรัฐ ประจำปี 2569: รางวัลบริการภาครัฐ ระดับดี ประเภทนวัตกรรมการบริการ).
The award recognizes the innovative healthcare project entitled:
“มะเร็งร้ายหายได้ด้วย PSU CAR-T Cell”
This achievement highlights the university's commitment to developing innovative cancer treatment services and strengthening access to advanced cellular therapies through academic research and clinical innovation.
The recognition also reflects the collaborative efforts of the PSU medical and research teams in translating scientific advances into practical healthcare applications.
Pioneering Clinical Research in PSU CAR-T Cell Therapy
As a leading principal investigator, Assoc. Prof. Dr. Jakrawadee Julamanee has played a central role in advancing CAR-T cell therapy research and clinical development at Prince of Songkla University.
One of her notable research initiatives is the clinical study entitled:
“Phase 1/2 Clinical Study to Assess the Safety and Efficacy of PSU CD19CAR-T Cell in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)”
Supported by PMU-ข, this study focuses on evaluating the safety and efficacy of locally developed CD19-directed Chimeric Antigen Receptor T-cell (CAR-T) therapy for patients with relapsed or refractory diffuse large B-cell lymphoma.
The research represents an important step toward strengthening Thailand's capacity to develop advanced cellular therapies and expanding potential treatment options for patients with difficult-to-treat hematologic malignancies.
Advancing Cancer Immunotherapy and Healthcare Innovation in Thailand
These national recognitions underscore the importance of integrating scientific research, clinical innovation, and healthcare service development to address the needs of cancer patients.
Through her leadership and dedication, Assoc. Prof. Dr. Jakrawadee continues to contribute to the advancement of academic CAR-T cell therapy, strengthening domestic research capabilities and supporting the development of innovative cancer treatment approaches in Thailand.
Her achievements also demonstrate the growing potential of Thai academic institutions to develop advanced biotherapies and translate research discoveries into meaningful clinical applications.
Celebrating Outstanding Research Leadership and Medical Innovation
The Thailand Hub of Talents in Cancer Immunotherapy (TTCI) extends its warmest congratulations to Assoc. Prof. Dr. Jakrawadee Julamanee and the คณะแพทยศาสตร์ มหาวิทยาลัยสงขลานครินทร์ on these remarkable national achievements.
These prestigious recognitions reflect her scientific excellence, visionary leadership, and dedication to advancing cancer immunotherapy research and healthcare innovation.
TTCI proudly celebrates these achievements and remains committed to fostering collaborative research, supporting scientific innovation, and advancing accessible cancer immunotherapy for patients across Thailand.
Official Website: www.ttci-th.org
